Alimera Sciences Inc (ALIM)

[rancher64]

ALIM's ILUVIEN is the best drug for DME

1. Market
DME patient population 575,000 in US. Around 20% annual growth rate. So by 2020, number of DME patients in US along will be around 1.2 million. Similar patient population in EU as well. Total over 2 million patients by 2020.

2. Pricing - 3 years treatment plan.
(a). Anti-VEGF drugs:

Lucentis: $17,550
Eylea : $27,750
Ozurdex : $9,750

(b). ILUVIEN : $8,800

3. Administration:
Anti-VEGF drugs: once a month or once every 2/3 months injections
ILUVIEN: Once in a 3 years injection.

4. Efficacy:
Anti-VEGF drugs do not work for 50% of the DME patient population, where ILUVIEN working with high efficacy and safety for all DME patient populations.

No doubt, ILUVIEN is the best drug candidate in this sector and only one of this kind. It's unique. That why patients are loving it and ALIM making massive sales growth. By 2020, if ALIM can get just 10% of 2M patients, it will make $600M sales. Also to note that patients would love to avoid every month or every 3 months injection, they would prefer every 3 years injection. So ILUVIEN demand will go up so as the pricing. This company has over billion dollar revenue potential in next 5 years. However I don't think, ALIM will still be around after 5 years - my DD say it will bought out by a big pharma before that.